Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anxiety associated with substance abuse].

Yu P Sivolap1

  • 1Sechenov First Moscow State Medical University, Moscow, Russia.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|March 17, 2017
PubMed
Summary

Anxiety and substance abuse, a dual diagnosis, often share underlying causes. Antidepressants, particularly SSRIs, are key for treating chronic anxiety in addiction, with other medications also showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Serotonin-norepinephrine reuptake inhibitors in psychiatry and neurology].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2021
Same author

[Systematics and treatment of anxiety disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2020
Same author

[Anxiety in neurological practice].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2020
Same author

[Challenges of the use of antipsychotics in children and adolescents].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2019
Same author

[Antipsychotics: treatment of schizophrenia and other therapeutic options].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2019
Same author

[Stroke and depression].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2019

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Substance abuse and anxiety frequently co-occur, presenting as a dual diagnosis in psychiatric practice.
  • The interdependence of these conditions and shared risk factors contribute to their comorbidity.

Purpose of the Study:

  • To review current pharmacological treatments for anxiety in patients with substance abuse disorders.
  • To highlight effective therapeutic strategies for managing comorbid anxiety and addiction.

Main Methods:

  • Literature review of pharmacological interventions for dual diagnosis patients.
  • Analysis of treatment efficacy for various anxiolytic medications in the context of substance abuse.

Main Results:

  • Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), are recommended for long-term treatment of chronic anxiety in substance abuse settings.
  • Other medications like pregabalin, buspirone, etifoxine, and alimemazine show potential for treating dual diagnosis patients.

Conclusions:

  • A long-term antidepressant regimen, primarily SSRIs, is a primary approach for chronic anxiety in patients with substance use disorders.
  • Several other pharmacological agents offer viable treatment options for the complex needs of dual diagnosis patients.

Related Experiment Videos